In prostate cancer, it was shown that AR can promote DNA repair through homologous recombination as its inhibition can mimic the loss-of-function of the breast cancer type 1 susceptibility protein (BRCA1) and confer cancer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Here, PARP1 is linked to prostate cancer.